CLINICAL_TRIALS ClinicalTrials.gov record update

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03793166
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:56.920922+00:00
Published At: 2026-04-13T00:00:00+00:00
Record Updated At: 2026-04-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Lymph Nodes", "Metastatic Malignant Neoplasm in the Soft Tissue", "Metastatic Malignant Neoplasm in the Viscera", "Rhabdoid Tumor of the Kidney", "Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-13"
protocolSection.identificationModule.nctId: "NCT03793166"
protocolSection.identificationModule.officialTitle: "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.